Related Experiment Video
Updated: Sep 16, 2026

Establishment and Characterization of UTI and CAUTI in a Mouse Model
Published on: June 23, 2015
[Clinical experience of netilmicin on chronic urinary tract infections (author's transl)]
Abstract:
Daily 150 mg or 200 mg dose of netilmicin (NTL) were administered to 26 patients with chronic complicated urinary tract infections for 5 days, and the following results were obtained. 1) Out of 26 cases excellent response was seen in 5 cases, good response in 4, and poor response in 11. Effectiveness rate was 45%. Six cases were excluded from the evaluation. 2) Effective result was not seen in the catheterized group, whereas 5 excellent and 4 good cases were observed in the noncatheterized group, resulting 60% in effectiveness rate. 3) MICs of NTL against various bacteria were comparative to GM against P. aeruginosa, to AMK against Serratia, and to both GM and AMK against other bacteria. 4) Except a slight local irritation, no subjective side effect was observed. One case showed a slight elevation in hepatic function tests but it was not definitely judged as the side effect due to NTL.
Insights
Netilmicin (NTL) showed a 45% effectiveness rate in treating chronic complicated urinary tract infections. The drug was more effective in non-catheterized patients, with no significant side effects observed.
Area of Science:
- Pharmacology
- Infectious Diseases
- Nephrology
Context:
- Chronic complicated urinary tract infections (UTIs) pose a significant clinical challenge.
- Antibiotic resistance necessitates evaluating novel therapeutic agents.
- Netilmicin (NTL) is an aminoglycoside antibiotic with potential utility in managing resistant bacterial infections.
Purpose:
- To evaluate the efficacy and safety of netilmicin (NTL) in patients with chronic complicated urinary tract infections.
- To compare the effectiveness of NTL in catheterized versus non-catheterized patient groups.
- To assess the in vitro activity of NTL against common UTI pathogens.
Summary:
- A total of 26 patients with chronic complicated UTIs received daily doses of 150 mg or 200 mg of netilmicin for 5 days.
- An overall effectiveness rate of 45% was observed, with better outcomes in non-catheterized patients (60% effectiveness).
- Netilmicin demonstrated comparable minimum inhibitory concentrations (MICs) to gentamicin (GM) and amikacin (AMK) against various bacteria, including Pseudomonas aeruginosa and Serratia species.
Impact:
- Netilmicin shows promise as a treatment option for chronic complicated UTIs, particularly in non-catheterized individuals.
- The study highlights the importance of patient factors, such as catheterization status, in treatment response.
- Netilmicin was generally well-tolerated, with minimal local irritation and no significant systemic adverse effects reported, suggesting a favorable safety profile.
More Related Videos
07:34Isolation of Single Intracellular Bacterial Communities Generated from a Murine Model of Urinary Tract Infection for Downstream Single-cell Analysis
Published on: April 16, 2019
07:39Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
Published on: June 14, 2021
Related Concept Videos
Urinary Tract Infection I: Introduction
Urinary Tract Infection II: Pathophysiology
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test